Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02706405
Title JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fred Hutchinson Cancer Research Center

B-cell lymphoma

diffuse large B-cell lymphoma


Cyclophosphamide + Durvalumab + JCAR014

Age Groups: adult
Covered Countries USA

No variant requirements are available.